The Cost of Enfortumab Vedotin Wastage Due to Vial Size—A Real-World Analysis
Enfortumab Vedotin (EV) is FDA-approved for advanced urothelial cancer in patients previously treated with platinum-based chemotherapy and a checkpoint inhibitor. We conducted a real-world study to determine the extent of EV wastage in a single institution and assessed the financial impact of EV was...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/23/5977 |
| _version_ | 1797508029771415552 |
|---|---|
| author | Michal Sarfaty Assaf Moore Ashley M. Regazzi Aaron P. Mitchell Jonathan E. Rosenberg |
| author_facet | Michal Sarfaty Assaf Moore Ashley M. Regazzi Aaron P. Mitchell Jonathan E. Rosenberg |
| author_sort | Michal Sarfaty |
| collection | DOAJ |
| description | Enfortumab Vedotin (EV) is FDA-approved for advanced urothelial cancer in patients previously treated with platinum-based chemotherapy and a checkpoint inhibitor. We conducted a real-world study to determine the extent of EV wastage in a single institution and assessed the financial impact of EV wastage annually in the United States. Systematic examination of the usage and wastage of all standard-of-care EV treatments administered to urothelial cancer patients at Memorial Sloan Kettering Cancer Center (MSKCC) between 1 January 2020 and 31 December 2020 was performed. Drug wastage was calculated by subtracting the actual administered dose from the total dose in an optimal set of vials. We built a pharmacoeconomic model to assess the financial impact of EV wastage annually in the US using the January 2021 Average Sales Prices from the Centers for Medicare and Medicaid Services. Sixty-four patients were treated with standard-of-care EV, with a median of 11 doses per patient (range 1–28). Wastage occurred in 46% of administered doses (367/793), with a mean waste per dose of 2.9% (0–18%). The average drug wastage cost per patient was $3127 ($252/dose). The annual cost of EV wastage in the US is estimated to be $15 million based on wastage data from a single center in the US. In summary, EV wastage due to available vial sizes was 2.9%, which falls under acceptable thresholds. While the percentage of EV wastage is relatively low, waste-minimizing practices may reduce the financial toxicity for the individual patient and for society. |
| first_indexed | 2024-03-10T04:56:49Z |
| format | Article |
| id | doaj.art-fdf11fe363744167a7fe5474743d39af |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T04:56:49Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-fdf11fe363744167a7fe5474743d39af2023-11-23T02:12:28ZengMDPI AGCancers2072-66942021-11-011323597710.3390/cancers13235977The Cost of Enfortumab Vedotin Wastage Due to Vial Size—A Real-World AnalysisMichal Sarfaty0Assaf Moore1Ashley M. Regazzi2Aaron P. Mitchell3Jonathan E. Rosenberg4Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USAOncology Department, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, IsraelGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USAGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USAGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USAEnfortumab Vedotin (EV) is FDA-approved for advanced urothelial cancer in patients previously treated with platinum-based chemotherapy and a checkpoint inhibitor. We conducted a real-world study to determine the extent of EV wastage in a single institution and assessed the financial impact of EV wastage annually in the United States. Systematic examination of the usage and wastage of all standard-of-care EV treatments administered to urothelial cancer patients at Memorial Sloan Kettering Cancer Center (MSKCC) between 1 January 2020 and 31 December 2020 was performed. Drug wastage was calculated by subtracting the actual administered dose from the total dose in an optimal set of vials. We built a pharmacoeconomic model to assess the financial impact of EV wastage annually in the US using the January 2021 Average Sales Prices from the Centers for Medicare and Medicaid Services. Sixty-four patients were treated with standard-of-care EV, with a median of 11 doses per patient (range 1–28). Wastage occurred in 46% of administered doses (367/793), with a mean waste per dose of 2.9% (0–18%). The average drug wastage cost per patient was $3127 ($252/dose). The annual cost of EV wastage in the US is estimated to be $15 million based on wastage data from a single center in the US. In summary, EV wastage due to available vial sizes was 2.9%, which falls under acceptable thresholds. While the percentage of EV wastage is relatively low, waste-minimizing practices may reduce the financial toxicity for the individual patient and for society.https://www.mdpi.com/2072-6694/13/23/5977enfortumab vedotinurothelial cancerdrug wastagevial size |
| spellingShingle | Michal Sarfaty Assaf Moore Ashley M. Regazzi Aaron P. Mitchell Jonathan E. Rosenberg The Cost of Enfortumab Vedotin Wastage Due to Vial Size—A Real-World Analysis Cancers enfortumab vedotin urothelial cancer drug wastage vial size |
| title | The Cost of Enfortumab Vedotin Wastage Due to Vial Size—A Real-World Analysis |
| title_full | The Cost of Enfortumab Vedotin Wastage Due to Vial Size—A Real-World Analysis |
| title_fullStr | The Cost of Enfortumab Vedotin Wastage Due to Vial Size—A Real-World Analysis |
| title_full_unstemmed | The Cost of Enfortumab Vedotin Wastage Due to Vial Size—A Real-World Analysis |
| title_short | The Cost of Enfortumab Vedotin Wastage Due to Vial Size—A Real-World Analysis |
| title_sort | cost of enfortumab vedotin wastage due to vial size a real world analysis |
| topic | enfortumab vedotin urothelial cancer drug wastage vial size |
| url | https://www.mdpi.com/2072-6694/13/23/5977 |
| work_keys_str_mv | AT michalsarfaty thecostofenfortumabvedotinwastageduetovialsizearealworldanalysis AT assafmoore thecostofenfortumabvedotinwastageduetovialsizearealworldanalysis AT ashleymregazzi thecostofenfortumabvedotinwastageduetovialsizearealworldanalysis AT aaronpmitchell thecostofenfortumabvedotinwastageduetovialsizearealworldanalysis AT jonathanerosenberg thecostofenfortumabvedotinwastageduetovialsizearealworldanalysis AT michalsarfaty costofenfortumabvedotinwastageduetovialsizearealworldanalysis AT assafmoore costofenfortumabvedotinwastageduetovialsizearealworldanalysis AT ashleymregazzi costofenfortumabvedotinwastageduetovialsizearealworldanalysis AT aaronpmitchell costofenfortumabvedotinwastageduetovialsizearealworldanalysis AT jonathanerosenberg costofenfortumabvedotinwastageduetovialsizearealworldanalysis |